Cancer Research Clinical Trials | AdventHealth Research Institute

Showing 97 - 108 of 154 clinical trials available

NCT05633654

GS-US-595-6184 A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63; NCT05633654)

This study is not currently enrolling.

Associated Conditions: Breast Cancer

Research Area: Clinical Cancer Research
Deep-learning of digital histopathology, radiomics and clinical factors to develop precision medicine with first-line gemcitabine-cisplatin-nivolumab for metastatic urothelial carcinoma: analysis of the CHECKMATE901 Phase III trial

This study is not currently enrolling.

Associated Conditions: Urothelial Cancer

Research Area: Clinical Cancer Research
NCT04585750

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

This study is not currently enrolling.

Research Area: Clinical Cancer Research

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors...
E303-1001S: A Phase I/II, Open-label, Multi-center, First-in-human Trial to Investigate E303 in Participants with Unresectable or Metastatic Solid Tumors and Urothelial Carcinoma

This study is not currently enrolling.

Research Area: Clinical Cancer Research
NCT05083481

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

This study is not currently enrolling.

Research Area: Clinical Cancer Research
A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This study is not currently enrolling.

Associated Conditions: Prostate Cancer

Research Area: Clinical Cancer Research
NCT05155332

Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors.

This study is not currently enrolling.

Research Area: Clinical Cancer Research
NCT06819007

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer” GOG 3112/ DSI-T-DXd ENHERTU (DO-01); DESTINY-Ovarian01 (DO-01)] DS8201-772

This study is not currently enrolling.

Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

This study consists of two parts: Part 1 (safety run-in) and Part 2 (randomized part [like the flip of a coin]). The purpose of Part 1 is to learn more about the safety and tolerability of the...
NCT05929235

A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

This study is not currently enrolling.

Associated Conditions: Multiple Tumor Types

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida
NCT05514717

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2

This study is not currently enrolling.

Associated Conditions: Metastatic Solid Tumors

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The purpose of the study is to: During the Dose Escalation part, find the most tolerated dose of the Study Drug that may provide potential benefit. During the Enrichment and Expansion parts, further...
NCT06456463

A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

This study is not currently enrolling.

Associated Conditions: Leukemia

Research Area: Clinical Cancer Research
NCT05858164

An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors

This study is not currently enrolling.

Associated Conditions: Metastatic Solid Tumors

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

This study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...